Biodexa Pharmaceuticals Files 6-K
Ticker: BDRX · Form: 6-K · Filed: Oct 4, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Oct 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, foreign-private-issuer
Related Tickers: BDRX
TL;DR
Biodexa Pharma (BDRX) filed a 6-K, confirming 20-F reporting. No major news yet.
AI Summary
Biodexa Pharmaceuticals Plc filed a Form 6-K on October 4, 2024, to report information as a foreign private issuer. The filing indicates that the company will file annual reports under Form 20-F. No specific financial transactions or operational updates were detailed in the provided excerpt.
Why It Matters
This filing serves as a routine update for investors and regulators regarding Biodexa Pharmaceuticals Plc's status as a foreign private issuer and its reporting obligations.
Risk Assessment
Risk Level: low — The filing is a standard procedural report and does not contain information that would immediately impact the company's risk profile.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Filer of the 6-K report
- 001-37652 (company) — Commission File Number
- Form 20-F (company) — Annual report form
- Form 6-K (company) — Report type
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC.
Which annual report form does Biodexa Pharmaceuticals Plc file?
Biodexa Pharmaceuticals Plc files its annual reports under cover of Form 20-F.
What is the Commission File Number for Biodexa Pharmaceuticals Plc?
The Commission File Number for Biodexa Pharmaceuticals Plc is 001-37652.
What is the principal executive office address for Biodexa Pharmaceuticals Plc?
The principal executive office address is 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom.
Does this filing contain specific financial or operational details?
The provided excerpt of the 6-K filing does not detail specific financial transactions or operational updates; it primarily serves as a procedural report.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 15.4 · Accepted 2024-10-04 08:30:09
Filing Documents
- f6k_100424.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-24-005504.txt ( ) — 17KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: October 4, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer